Midday movers: Tesla, Rivian rise; Novo Nordisk, Pure Storage fall

Go back to Midday movers: Tesla, Rivian rise; Novo Nordisk, Pure Storage fall

Eli Lilly, Novo Nordisk shares fall as Ozempic, Wegovy tied to rare cases of vision loss

July 3, 2024 11:49 AM EDT

Novo Nordisk (NYSE: NVO) shares are down almost 4%, while Eli Lilly & Co. (NYSE: LLY) has dropped more than 1% Wednesday after a report from the New York Post said there is a potential link between Ozempic and a serious eye condition.

The publication, citing a new... More

Pharma selloff overdone: JPMorgan

July 3, 2024 7:43 AM EDT

JPMorgan analysts downplayed concerns over drug pricing that triggered a broad healthcare and pharmaceutical sector sell-off, calling it "overdone election noise."

"Pricing has always been a popular issue to comment on but tough to follow through, also more complicated with the Inflation Reduction Act (IRA) now," the bank stated.... More

Wolfe Asks: 'Has Tesla's (TSLA) sleeping giant finally awoken?'

July 3, 2024 7:18 AM EDT

Wolfe Asks: 'Has TTesla (NASDAQ: TSLA) sleeping giant finally awoken?'

The analyst comments "Tesla reported better than expected Q2 deliveries of 444k vehicles (-4.8% y/y), ahead of Consensus at 437.8k and wellahead of our estimate of 419k (we think buyside expectations were in the ~420k range). Meanwhile, with production down 14.4% y/y (to 410.8k), TSLA was able to meaningful reduce in-transit... More

JPMorgan on Tesla (TSLA): 'We estimate Tesla also lost ground vs. the total auto industry'

July 3, 2024 4:55 AM EDT

JPMorgan analyst Ryan Brinkman reiterated an Underweight rating and $115.00 price target on Tesla (NASDAQ: TSLA)

The analyst comments "TSLA shares rallied +10.2% Tuesday vs. the S&P 500 +0.6%, ostensibly upon the release of 2Q24 sales and production figures, which showed that Teslas vehicle deliveries... More

BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)

July 2, 2024 3:04 PM EDT

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,001.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments "Approval of donanemab (branded Kisunla) is likely to expand revenue for both Lilly and Biogen/Eisai as two players are needed to grow infrastructure.... More

Morgan Stanley on Eli Lilly (LLY): 'we expect LLY shares to trade flat to slightly up'

July 2, 2024 2:41 PM EDT

Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,023.00 price target on Eli Lilly (NYSE: LLY)

The analyst comments "The approval was in line with our expectations and we expect LLY shares to trade flat to slightly up as a result. For... More

CFRA Reiterates Sell Rating on Rivian Automotive Inc (RIVN)

July 2, 2024 1:45 PM EDT

CFRA analyst Garrett Nelson reiterated a Sell rating and $8.00 price target on Rivian Automotive Inc (NASDAQ: RIVN).

The analyst comments "We maintain our 12-month target of $8, comparable to EV peers. We cut our 2024 adjusted EPS view to -$4.35 from -$4.10 and keep 2025's at -$3.15. RIVN... More

Truist on Tesla (TSLA): 'we believe lower production may be related to retooling for new model introductions, and will help reduce inventory'

July 2, 2024 1:00 PM EDT

Truist Securities analyst William Stein reiterated a Hold rating and $162.00 price target on Tesla (NASDAQ: TSLA)

The analyst comments " 2Q24 deliveries are slightly above consensus; we expect reduced production to help normalize inventory levels. Earlier today, TSLA announced Q2 unit deliveries were 444k in the quarter (down 5% y/y), 1.7%... More

Stifel: 2Q24 delivery numbers from Tesla, Rivian positive for shares

July 2, 2024 12:57 PM EDT

Stifel analysts believe strong delivery numbers for Tesla (NASDAQ: TSLA) and Rivian Automotive (NASDAQ: RIVN) in the second quarter of 2024 (2Q24) will positively impact their share prices.

Tesla surpassed analyst expectations with deliveries of 443,956, exceeding Stifel's estimate of... More

Tesla (TSLA) PT Raised to $254 at Canaccord Genuity, 'We are autonomy uber-bulls'

July 2, 2024 12:25 PM EDT

Canaccord Genuity analyst George Gianarikas raised the price target on Tesla (NASDAQ: TSLA) to $254.00 (from $222.00) while maintaining a Buy rating.

The analyst comments "The most important question going into earnings. Teslas upcoming earnings report after the market close on July 23rd will bring lots of new information: margin results, (possible) details on new vehicles, energy storage... More